GENOVA DIAGNOSTICS
63 Zillicoa Street
Asheville, NC 28801
© Genova Diagnostics

GI effects® | DIG

Patient: **SAMPLE PATIENT**

## 2226 GI Effects® DIG - Stool

*Methodologies: GC-FID, Automated Chemistry, ELISA*

| | Result | QUINTILE DISTRIBUTION (1st 2nd 3rd 4th 5th) | Reference Range |
|---|---|---|---|
| **Digestion and Absorption** | | | |
| Pancreatic Elastase 1 † | >500 | 100 200 | >200 mcg/g |
| Products of Protein Breakdown (Total*) (Valerate, Isobutyrate, Isovalerate) | 2.2 | | 1.8-9.9 micromol/g |
| Fecal Fat (Total*) | 6.6 | | 3.2-38.6 mg/g |
| Triglycerides | 0.7 | | 0.3-2.8 mg/g |
| Long-Chain Fatty Acids | 4.6 | | 1.2-29.1 mg/g |
| Cholesterol | 0.8 | | 0.4-4.8 mg/g |
| Phospholipids | 0.5 | | 0.2-6.9 mg/g |
| **Inflammation and Immunology** | | | |
| Calprotectin † ◆ | <16 | 50 120 | <50 mcg/g |
| Eosinophil Protein X (EPX) † | <DL | 0.5 2.7 | <=2.7 mcg/g |
| Fecal secretory IgA | 683 | 680 2040 | <=2,040 mcg/mL |
| **Gut Microbiome Metabolites** | | | |
| **Metabolic** | | | |
| Short-Chain Fatty Acids (SCFA) (Total*) (Acetate, n-Butyrate, Propionate) | 29.3 | | >=23.3 micromol/g |
| n-Butyrate Concentration | 6.7 | | >=3.6 micromol/g |
| n-Butyrate % | 22.9 | | 11.8-33.3 % |
| Acetate % | 59.2 | | 48.1-69.2 % |
| Propionate % | 18.1 | | <=29.3 % |
| Beta-glucuronidase | 1,547 | | 368-6,266 U/g |

**Total value is equal to the sum of all measurable parts.*
*†These results are not represented by quintile values.*

## Additional Results

| | Result |
|---|---|
| Color†† | Light Brown |
| Consistency†† | Formed/Normal |

††Results provided from patient input.

## Lab Comments

A modified version of the assay cleared by the US Food and Drug Administration is used to measure PE1. Performance characteristics were confirmed or determined by Genova Diagnostics, Inc. in a manner consistent with CLIA requirements.

Commentary is provided to the practitioner for educational purposes and should not be interpreted as diagnostic or as treatment recommendations. Diagnosis and treatment decisions are the practitioner's responsibility.

The performance characteristics of all assays have been verified by Genova Diagnostics, Inc. Unless otherwise noted with ◆, the assay has not been cleared by the U.S. Food and Drug Administration.

For more information regarding GI Effects clinical interpretation, please refer to the GI Effects Support Guide at **www.gdx.net/gieffectsguide**